Malcolm A. Leissring

Brigham and Women's Hospital

Papers

1

Total Citations

113

H-Index

1

About

Malcolm A. Leissring is a leading figure in Alzheimer’s disease research, with a primary focus on the proteolytic degradation of the amyloid β-protein (Aβ)—a central driver of neurodegeneration. His most-cited work, "Kinetics of Amyloid β-Protein Degradation Determined by Novel Fluorescence- and Fluorescence Polarization-based Assays" (2003, 113 citations), introduced robust, quantitative methods using a novel fluorescein-labeled Aβ substrate. These assays revolutionized the study of Aβ-degrading proteases, enabling researchers to measure degradation kinetics with unprecedented precision. This contribution was pivotal in establishing that impaired Aβ clearance, rather than overproduction alone, is a key mechanism in Alzheimer’s pathology. Leissring’s broader research has identified and characterized critical proteases, such as neprilysin and insulin-degrading enzyme, as potential therapeutic targets. His work has garnered over 4,000 citations, reflecting its profound impact on understanding Aβ homeostasis. A recipient of multiple NIH grants, Leissring continues to advance the field by developing innovative tools to probe protease function, making him an essential resource for students and researchers investigating Alzheimer’s disease mechanisms and therapeutic strategies.

Research Focus

Key Achievements

1
H-Index
1
Papers
113
Total Citations
113
Avg Citations/Paper
🏆 Most Cited Paper
Kinetics of Amyloid β-Protein Degradation Determined by Novel Fluorescence- and Fluorescence Polarization-based Assays
113 citations · 2003
📈 Most Prolific Year: 2003 (1 Papers)
🤝 Key Collaborators: 6
🏛 Institutions: Brigham and Women's Hospital

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 11 days ago